Codoxo
Codoxo develops a Forensic AI Platform using a patented algorithm to identify fraud, waste, and abuse in healthcare claims.
Secondary Market Price
Secondary Market Price
How Codoxo Measures Up
To help you manage your Codoxo equity, Prospect has run the company through our machine learning model.
Prospect Rating
TBD
We are still gathering data to complete our evaluation of Codoxo. Please check back soon for our rating and four-year projection of the company's worth.
Exit Risk
TBD
We are still gathering data on Codoxo to train our machine learning model. Check back soon for our exit risk rating for Codoxo!
Funding Stage
Series B
As a Series B company, Codoxo has successfully moved beyond the initial startup risks and is now focused on expanding its established presence in the market. For you, this means joining a company that offers more stability than an early-stage venture while still providing significant opportunities for growth and impact.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Codoxo's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Codoxo Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Codoxo's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Codoxo provides an AI-assisted platform for the healthcare industry focused on identifying fraud, waste, and abuse. The company’s core offering is its Forensic AI Platform, which utilizes a patented algorithm to detect suspicious behavior and payment issues earlier than traditional methods. Its products, which include Fraud Scope, Provider Scope, and Point Zero Payment Integrity, are designed to help health plans investigate claims and prevent improper payments. Founded in 2016 by Musheer Ahmed and Dr. Mustaque Ahamad, the company was originally named Fraudscope. It has since rebranded to Codoxo and has raised a total of $32.1 million through multiple funding rounds, including a Series B round.
Looking forward, Codoxo plans to continue developing its AI capabilities, with an emphasis on pre-claim intervention through its Point Zero Payment Integrity model. The company is also expanding its use of generative AI for Special Investigations Units, including tools for deep fake detection in document reviews. Recently, Codoxo’s Point Zero solution was named a finalist in two categories for the 2025 A.I. Awards: Most Innovative AI Technology and Best Use of AI for Healthcare. The company is also increasing its industry presence, sponsoring events like the HealthEdge Leadership Forum 2025 and participating in the NHCAA 2025 conference. At a recent customer conference, Codoxo previewed its 2026 product roadmap and launched a new booklet series on proactive payment integrity.
- QED Investors
- Sands Capital Ventures
- 111 West Capital
- Brewer Lane Ventures
- Spider Capital
- GRA Venture Fund
- TechSquare Labs
- Wipro Ventures
- Southern Equity Advisors
- Biolocity
- Co-Founder, CEO Musheer Ahmed
- Co-Founder, Chief Scientist Mustaque Ahamad
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Codoxo worth joining?
Evaluating whether a startup like Codoxo is a good fit requires analyzing its growth potential, financial stability, and the value of its equity offer. Tools like Prospect can help you assess these factors using data and models similar to those used by venture capitalists.
What should I do with my Codoxo stock?
Deciding what to do with private company stock involves creating a financial strategy that balances tax implications, risk, and personal goals. Equity management platforms such as Prospect provide tools to help you model scenarios and create a personalized plan for your Codoxo shares.
Can you sell Codoxo stock?
Since Codoxo is a private company, selling stock is generally possible only during specific events like company-approved tender offers or on secondary markets. These opportunities are not always available and are often subject to restrictions and right of first refusal from the company.
How can I find the value of my Codoxo stock?
The value of private stock is typically determined by the company's most recent 409A valuation, which is used for tax purposes. For a more comprehensive projection, platforms like Prospect use predictive models and market data to help you estimate the potential future worth of your equity.
What is Codoxo's equity worth?
A company's total equity worth is based on its latest valuation, but the value of your individual shares is determined by factors like the 409A valuation and share price. You can use an equity calculator to estimate what your specific holdings in Codoxo could be worth based on various outcomes.
What is Codoxo's stock ticker symbol?
As a private company, Codoxo does not have a stock ticker symbol because its shares are not traded on public exchanges like the NYSE or NASDAQ. Ticker symbols are only assigned to companies after they complete an Initial Public Offering (IPO).
Can I buy or sell Codoxo stock?
Buying stock in a private company like Codoxo is generally restricted to accredited investors during funding rounds, and selling is usually limited to company-approved events like tender offers. Tools from platforms like Prospect can help you understand your options and make informed decisions during these liquidity events.
What is the criteria to buy or invest in Codoxo stock?
Investing in a private company like Codoxo generally requires being an accredited investor and having access to its funding rounds. To evaluate the opportunity, you should analyze its growth metrics, market position, and leadership team, using resources like Prospect to gather data-driven insights.
